Treatment of progressive multiple sclerosis: What works, what does not, and what is needed

The Lancet Neurology

Volumn 14, Issue 2, 2015, Pages 194-207

  Feinstein, Anthony ^a   Freeman, Jenny ^b   Lo, Albert C ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; IMMUNOLOGIC FACTOR;

ARTICLE; ATAXIA; BALANCE IMPAIRMENT; BLADDER DYSFUNCTION; COGNITIVE DEFECT; DEPRESSION; DISEASE COURSE; FATIGUE; FITNESS; HUMAN; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; PAIN; PREVALENCE; PRIORITY JOURNAL; SPASTICITY; WEAKNESS; ANIMAL; DRUG EFFECTS; HEALTH SERVICE; KINESIOTHERAPY; MUSCLE FATIGUE; PHYSIOTHERAPY; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME; TRENDS;

ANIMALS; DEPRESSION; EXERCISE THERAPY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; MUSCLE FATIGUE; PHYSICAL THERAPY MODALITIES; TREATMENT OUTCOME;

EID: 84922554905     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70231-5     Document Type: Review

References (121)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. The IFNB Multiple Sclerosis Study Group.
2. Mantia LL, Vacchi L, Rovaris M, et al. Interferon β for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry 2013, 84:420-426.
3. Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008, 14:988-991.
4. Miller DM, Allen R Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice. Curr Neurol Neurosci Rep 2010, 10:397-406.
5. Martin CL, Phillips BA, Kilpatrick TJ, et al. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 2006, 12:620-628.
6. Snook EM, Motl RW Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair 2009, 23:108-116.
7. Kesselring J, Beer S Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005, 4:643-652.
8. Cattaneo D, Jonsdottir J Sensory impairments in quiet standing in subjects with multiple sclerosis. Mult Scler 2009, 15:59-67.
9. Hoang PD, Gandevia SC, Herbert RD Prevalence of joint contractures and muscle weakness in people with multiple sclerosis. Disabil Rehabil 2014, 36:1588-1593.
10. Kjølhede T, Vissing K, Dalgas U Multiple sclerosis and progressive resistance training: a systematic review. Mult Scler 2012, 18:1215-1228.
11. Mills RJ, Yap L, Young CA Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev 2007, 1. CD005029.
12. Induruwa I, Constantinescu CS, Gran B Fatigue in multiple sclerosis-a brief review. J Neurol Sci 2012, 323:9-15.
13. Bakke A, Myhr KM, Grønning M, Nyland H Bladder, bowel and sexual dysfunction in patients with multiple sclerosis-a cohort study. Scand J Urol Nephrol Suppl 1996, 179:61-66.
14. DasGupta R, Fowler CJ Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003, 63:153-166.
15. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004, 10:589-595.
16. Foley PL, Vesterinen HM, Laird BJ, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain 2013, 154:632-642.
17. Denney DR, Sworowski LA, Lynch SG Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol 2005, 20:967-981.
18. Ruet A, Deloire M, Charré-Morin J, Hamel D, Brochet B Cognitive impairment differs between primary progressive and relapsing-remitting MS. Neurology 2013, 80:1501-1508.
19. Minden SL, Schiffer RB Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol 1990, 47:98-104.
20. Feinstein A, Feinstein K, Gray T, O'Connor P Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997, 54:1116-1121.
21. Paltamaa J, Sjögren T, Peurala SH, Heinonen A Effects of physiotherapy interventions on balance in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. J Rehabil Med 2012, 44:811-823.
22. Armutlu K, Karabudak R, Nurlu G Physiotherapy approaches in the treatment of ataxic multiple sclerosis: a pilot study. Neurorehabil Neural Repair 2001, 15:203-211.
23. Swinnen E, Beckwee D, Pinte D, Meeusen R, Baeyens JP, Kerckhofs E Treadmill training in multiple sclerosis: can body weight support or robot assistance provide added value? A systematic review. Mult Scler Int 2012, 2012:24074.
24. Pilutti LA, Lelli DA, Paulseth JE, et al. Effects of 12 weeks of supported treadmill training on functional ability and quality of life in progressive multiple sclerosis: a pilot study. Arch Phys Med Rehabil 2011, 92:31-36.
25. Briken S, Gold SM, Patra S, et al. Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. Mult Scler 2014, 20:382-390.
26. Latimer-Cheung AE, Pilutti LA, Hicks AL, et al. Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development. Arch Phys Med Rehabil 2013, 94:1800-1828.
27. Yadav V, Bever C, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2014, 82:1083-1092.
28. Fonteyn EM, Keus SH, Verstappen CC, Schöls L, de Groot IJ, van de Warrenburg BP The effectiveness of allied health care in patients with ataxia: a systematic review. J Neurol 2014, 261:251-258.
29. Marquer A, Barbieri G, Perennou G The assessment and treatment of postural disorders in cerebellar ataxia: a systematic review. Ann Phys Rehabil Med 2014, 57:67-78.
30. Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007, 1. CD002818.
31. Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2012, 5. CD007280.
32. Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JB, van Meeteren J Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Arch Phys Med Rehabil 2013, 94:1360-1376.
33. Vanage SM, Gilbertson KK, Mathiowetz V Effects of an energy conservation course on fatigue impact for persons with progressive multiple sclerosis. Am J Occup Ther 2003, 57:315-323.
34. Pilutti LA, Greenlee TA, Motl RW, Nickrent MS, Petruzzello SJ Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis. Psychosom Med 2013, 75:575-580.
35. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011, 60:742-750.
36. De Ridder D, Van Poppel H, Baert L, Binard J From time dependent intermittent selfcatheterisation to volume dependent selfcatheterisation in multiple sclerosis using the PCI 5000 Bladdermanager. Spinal Cord 1997, 35:613-616.
37. Prasad RS, Smith SJ, Wright H Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003, 17:42-47.
38. De Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg 1999, 99:61-64.
39. van Rey F, Heesakkers J Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol 2011, 2011:834753.
40. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007, 21:331-337.
41. Velikonja O, Curić K, Ozura A, Jazbec SS Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg 2010, 112:597-601.
42. Miller L, Mattison P, Paul L, Wood L The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 2007, 13:527-533.
43. Ratchford JN, Shore W, Hammond ER, et al. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. NeuroRehabilitation 2010, 27:121-128.
44. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008, 14:1076-1083.
45. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011, 18:1122-1131. the Sativex Spasticity Study Group.
46. Wier LM, Hatcher MS, Triche EW, Lo AC Effect of robot-assisted versus conventional body-weight-supported treadmill training on quality of life for people with multiple sclerosis. J Rehabil Res Dev 2011, 48:483-492.
47. Warke K, Al-Smadi J, Baxter D, Walsh DM, Lowe-Strong AS Efficacy of transcutaneous electrical nerve stimulation (tens) for chronic low-back pain in a multiple sclerosis population: a randomized, placebo-controlled clinical trial. Clin J Pain 2006, 22:812-819.
48. Miller L, Mattison P, Paul L, Wood L The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 2007, 13:527-533.
49. Negahban H, Rezaie S, Goharpey S Massage therapy and exercise therapy in patients with multiple sclerosis: a randomized controlled pilot study. Clin Rehabil 2013, 27:1126-1136.
50. Schyns F, Paul L, Finlay K, Ferguson C, Noble E Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance. Clin Rehabil 2009, 23:771-781.
51. Solaro C, Trabucco E, Messmer Uccelli M Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep 2013, 13:320.
52. Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, DeLuca J L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler 2011, 17:1141-1145.
53. Benedict RH, Munschauer F, Zarevics P, et al. Effects of L-amphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol 2008, 255:848-852.
54. Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011, 76:1500-1507.
55. Chiaravalloti ND, DeLuca J, Moore NB, Ricker JH Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult Scler 2005, 11:58-68.
56. Chiaravalloti ND, Moore NB, Nikelshpur OM, DeLuca J An RCT to treat learning impairment in multiple sclerosis: the MEMREHAB trial. Neurology 2013, 81:2066-2072.
57. Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De Keyster J Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev 2011, 16. CD007295.
58. Thomas PW, Thomas S, Hillier C, Galvin K, Baker R Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev 2006, 25. CD004431.
59. Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014, 82:174-181. the Guideline Development Subcommittee of the American Academy of Neurology.
60. Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler 2012, 18:1534-1540.
61. Soyuer F, Mirza M, Erkorkmaz U Balance performance in three forms of multiple sclerosis. Neurol Res 2006, 28:555-562.
62. Gunn HJ, Newell P, Haas B, Marsden JF, Freeman JA Identification of risk factors for falls in multiple sclerosis: a systematic review and meta-analysis. Phys Ther 2013, 93:504-513.
63. Giannì C, Prosperini L, Jonsdottir J, Cattaneo D A systematic review of factors associated with accidental falls in people with multiple sclerosis: a meta-analytic approach. Clin Rehabil 2014, 28:704-716.
64. Cameron MH, Poel AJ, Haselkorn JK, Linke A, Bourdette D Falls requiring medical attention among veterans with multiple sclerosis: a cohort study. J Rehabil Res Dev 2011, 48:13-20.
65. Peterson EW, Cho CC, Finlayson ML Fear of falling and associated activity curtailment among middle aged and older adults with multiple sclerosis. Mult Scler 2007, 13:1168-1175.
66. Prosperini L, Pozzilli C The clinical relevance of force platform measures in multiple sclerosis: a review. Mult Scler Int 2013, 2013:756564.
67. Morgen K, Kadom N, Sawaki L, et al. Training-dependent plasticity in patients with multiple sclerosis. Brain 2004, 127:2506-2517.
68. Tomassini V, Johansen-Berg H, Leonardi L, et al. Preservation of motor skill learning in patients with multiple sclerosis. Mult Scler 2011, 17:103-115.
69. Giesser B, Beres-Jones J, Budovitch A, Herlihy E, Harkema S Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler 2007, 13:224-231.
70. Guclu-Gunduz A, Citaker S, Nazliel B, Irkec C Upper extremity function and its relation with hand sensation and upper extremity strength in patients with multiple sclerosis. Neurorehabilitation 2012, 30:369-374.
71. Gosselink R, Kovacs L, Ketelaer P, Carton H, Decramer M Respiratory muscle weakness and respiratory muscle training in severely disabled multiple sclerosis patients. Arch Phys Med Rehabil 2000, 81:747-751.
72. Thoumie P, Lamotte D, Cantalloube S, Faucher M, Amarenco G Motor determinants of gait in 100 ambulatory patients with multiple sclerosis. Mult Scler 2005, 11:485-491.
73. Jensen HB, Ravnborg M, Dalgas U, Stenager E 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2014, 7:97-113.
74. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001, 7:354-358.
75. Nortvedt MW, Riise T, Maeland JG Multiple sclerosis and lifestyle factors: the Hordaland Health Study. Neurol Sci 2005, 26:334-339.
76. Skjerbæk AG, Møller AB, Jensen E, et al. Heat sensitive persons with multiple sclerosis are more tolerant to resistance exercise than to endurance exercise. Mult Scler 2013, 19:932-940.
77. Feinstein A, Dalgas U The benefits of exercise in progressive MS: some cautious optimism. Mult Scler 2014, 20:269-270.
78. Marsden J, Harris C Cerebellar ataxia: pathophysiology and rehabilitation. Clin Rehabil 2011, 25:195-216.
79. Baram Y, Miller A Virtual reality cues for improvement of gait in patients with multiple sclerosis. Neurology 2006, 66:178-181.
80. Gill-Body KM, Popat RA, Parker SW, Krebs DE Rehabilitation of balance in two patients with cerebellar dysfunction. Phys Ther 1997, 77:534-552.
81. Vergaro E, Squeri V, Brichetto G, et al. Adaptive robot training for the treatment of incoordination in multiple sclerosis. J Neuroeng Rehabil 2010, 7:37.
82. Koch G, Rossi S, Prosperetti C, et al. Improvement of hand dexterity following motor cortex rTMS in multiple sclerosis patients with cerebellar impairment. Mult Scler 2008, 14:995-998.
83. Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000, 4:1-61.
84. Andreasen AK, Stenager E, Dalgas U The effect of exercise therapy on fatigue in multiple sclerosis. Mult Scler 2011, 17:1041-1054.
85. Hebert JR, Corboy JR, Manago MM, Schenkman M Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial. Phys Ther 2011, 91:1166-1183.
86. van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med 2008, 70:205-213.
87. Thomas S, Thomas PW, Kersten P, et al. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psychiatry 2013, 84:1092-1099.
88. Patti F, Ciancio MR, Reggio E, et al. The impact of outpatient rehabilitation on quality of life in multiple sclerosis. J Neurol 2002, 249:1027-1033.
89. Vikman T, Fielding P, Lindmark B, Fredrikson S Effects of inpatient rehabilitation in multiple sclerosis patients with moderate disability. Adv Physiother 2008, 10:58-65.
90. Fischer A, Heesen C, Gold SM Biological outcome measurements for behavioral interventions in multiple sclerosis. Ther Adv Neurol Disord 2011, 4:217-229.
91. Huolman S, Hämäläinen P, Vorobyev V, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler 2011, 17:1351-1361.
92. Mainero C, Inghilleri M, Pantano P, et al. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology 2004, 62:2044-2050.
93. Nortvedt MW, Riise T, Frugård J, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007, 13:106-112.
94. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007, 62:452-457.
95. Stevenson VL Rehabilitation in practice: spasticity management. Clin Rehabil 2010, 24:293-304.
96. Shakespeare D, Boggild M, Young CA Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003, 4. CD001332.
97. Mori F, Ljoka C, Magni E, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol 2011, 258:1281-1287.
98. Kalia LV, O'Connor PW Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005, 11:322-327.
99. Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain 2007, 127:35-41.
100. Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C Symptomatic medication use in multiple sclerosis. Mult Scler 2003, 9:458-460.
101. Sadiq SA, Poopatana CA Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol 2007, 254:1464-1465.
102. Loitfelder M, Fazekas F, Petrovic K, et al. Reorganization in cognitive networks with progression of multiple sclerosis: insights from fMRI. Neurology 2011, 76:526-533.
103. Rocca MA, Valsasina P, Absinta M, et al. Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology 2010, 74:1252-1259.
104. Sumowski JF, Chiaravalloti N, Leavitt VM, Deluca J Cognitive reserve in secondary progressive multiple sclerosis. Mult Scler 2012, 18:1454-1458.
105. Strober LB, Christodoulou C, Benedict RH, et al. Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler 2012, 18:647-653.
106. Grasso MG, Troisi E, Rizzi F, Morelli D, Paolucci S Prognostic factors in multidisciplinary rehabilitation treatment in multiple sclerosis: an outcome study. Mult Scler 2005, 11:719-724.
107. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F European Study Group in Final Analysis of the European multicenter trial of INFbeta-1b in secondary progressive NMS. Neurology 2001, 57:1169-1175.
108. Montalban X, Sastre-Garriga J, Tintoré M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009, 15:1195-1205.
109. Harel Y, Appleboim N, Lavie M, Achiron A Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci 2009, 276:38-40.
110. Wilken JA, Sullivan C, Wallin M, et al. Treatment of multiple sclerosis-related cognitive problems with adjunctive modafinil: rationale and preliminary supportive data. Int J MS Care 2008, 10:1-10.
111. Rosti-Otajärvi EM, Hämäläinen PI Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev 2011, 9. CD009131.
112. Chiaravalloti ND, Wylie G, Leavitt V, Deluca J Increased cerebral activation after behavioral treatment for memory deficits in MS. J Neurol 2012, 259:1337-1346.
113. Koch M, Uyttenboogaart M, van Harten A, Heerings M, De Keyser J Fatigue, depression and progression in multiple sclerosis. Mult Scler 2008, 14:815-822.
114. Vleugels L, Pfennings L, Pouwer F, et al. Psychological functioning in primary progressive versus secondary progressive multiple sclerosis. Br J Med Psychol 1998, 71:99-106.
115. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004, 62:586-590.
116. Lynch SG, Kroencke DC, Denney DR The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope. Mult Scler 2001, 7:411-416.
117. Stenager EN, Stenager E Suicide and patients with neurologic diseases. Methodologic problems. Arch Neurol 1992, 49:1296-1303.
118. Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A Health-related quality of life and depressive symptoms in significant others of people with multiple sclerosis: a community study. Eur J Neurol 2012, 19:847-854. the POSMOS study.
119. Mohr DC, Hart SL, Fonareva I, Tasch ES Treatment of depression for patients with multiple sclerosis in neurology clinics. Mult Scler 2006, 12:204-208.
120. Feinstein A, Rector N, Motl R Exercising away the blues: can it help multiple sclerosis-related depression?. Mult Scler 2013, 19:1815-1819.
121. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134:1914-1924.